Adma Biologics, Inc.
A maker of plasma-derived medicines for people with weakened immune systems, ADMA Biologics produces immune globulin therapies such as BIVIGAM and Nabi-HB, used to treat primary immunodeficiency and to guard against hepatitis B. The company was formed in 2013 when ADMA Biologics merged with Nabi Biologics, combining their plasma collection and manufacturing operations. Headquartered in Boca Raton, Florida, it collects plasma and turns it into treatments for immune deficiency patients.
Sold 1.54M
Granted 439.7K · Bought 14.0K · Sold 1.93M
Granted 6.52M · Bought 380.0K · Sold 1.79M
Granted 76.4K · Sold 1.43M
Granted 1.98M · Bought 37.0K · Sold 389.8K
Granted 244.9K · Bought 261.4K · Sold 146.9K
Granted 403.5K · Sold 34.2K
Granted 146.0K · Sold 38.0K
Granted 98.0K · Bought 125.0K · Sold 60.0K
Granted 134.6K · Sold 15.0K
Granted 52.4K
Granted 45.6K
Granted 21.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Edelman Joseph +2 co-filers10% owner · 6 transactions | -10.4% | 13.26Mas of Sep 2021 | — | — | 1.54M |
| Elms SteveDirector · 26 transactions | — | 6.21M | 439.7K | 14.0K | 1.93M |
| Grossman Adam SPresident and CEO, Director · 98 transactions | +107% | 3.84M | 6.52M | 380.0K | 1.79M |
| Fong BryantDirector · 4 transactions | — | 1.52Mas of Feb 2024 | 76.4K | — | 1.43M |
| Lenz BrianEVP, CFO · 31 transactions | +401.9% | 703.0Kas of Mar 2024 | 1.98M | 37.0K | 389.8K |
| Grossman Jerrold BDirector · 16 transactions | +141.7% | 613.0K | 244.9K | 261.4K | 146.9K |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance · 33 transactions | — | 446.2K | 403.5K | — | 34.2K |
| Guiheen Lawrence P.Director · 15 transactions | — | 373.0K | 146.0K | — | 38.0K |
| Kwon YoungDirector · 8 transactions | — | 263.0K | 98.0K | 125.0K | 60.0K |
| Tade Brad L.CFO and Treasurer · 7 transactions | — | 232.9K | 134.6K | — | 15.0K |
| Demski Martha JDirector · 2 transactions | +1247.6% | 56.6Kas of Mar 2023 | 52.4K | — | — |
| Finger Alison CecilyDirector · 3 transactions | — | 45.6K | 45.6K | — | — |
| Salas Eduardo ReneDirector · 2 transactions | — | 21.6K | 21.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -6.55M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.